Irreversible corneal decompensation in patients treated with topical dorzolamide.


PURPOSE To describe irreversible corneal decompensation after topical dorzolamide hydrochloride (Trusopt; Merck and Co, Inc, West Point, Pennsylvania) therapy in nine patients who had histories consistent with corneal endothelial compromise. METHOD Multicenter review of patients' charts. RESULTS Nine eyes of nine patients developed overt corneal… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.